Literature DB >> 22185184

Real economics needs to reflect real decisions: a response to Johnson.

Mark Sculpher1, Karl Claxton.   

Abstract

Mesh：

Year:  2012        PMID： 22185184     DOI： 10.2165/11596660-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  12 in total

1.  Why not real economics?

Authors:  F Reed Johnson
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

2.  Willingness to pay for a QALY: past, present and future.

Authors:  Helen Mason; Rachel Baker; Cam Donaldson
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2008-12       Impact factor: 2.217

3.  Does health care spending improve health outcomes? Evidence from English programme budgeting data.

Authors:  Stephen Martin; Nigel Rice; Peter C Smith
Journal:  J Health Econ       Date:  2007-12-25       Impact factor: 3.883

4.  Welfarism vs. extra-welfarism.

Authors:  Werner B F Brouwer; Anthony J Culyer; N Job A van Exel; Frans F H Rutten
Journal:  J Health Econ       Date:  2007-11-29       Impact factor: 3.883

Review 5.  The NICE cost-effectiveness threshold: what it is and what that means.

Authors:  Christopher McCabe; Karl Claxton; Anthony J Culyer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  Ten arguments for a societal perspective in the economic evaluation of medical innovations.

Authors:  Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2009-10

7.  Quality-adjusted life years, utility theory, and healthy-years equivalents.

Authors:  A Mehrez; A Gafni
Journal:  Med Decis Making       Date:  1989 Apr-Jun       Impact factor: 2.583

8.  Focusing technology assessment using medical decision theory.

Authors:  C E Phelps; A I Mushlin
Journal:  Med Decis Making       Date:  1988 Oct-Dec       Impact factor: 2.583

9.  Cost-benefit analysis.

Authors:  R Robinson
Journal:  BMJ       Date:  1993-10-09

10.  Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence.

Authors:  Anthony Culyer; Christopher McCabe; Andrew Briggs; Karl Claxton; Martin Buxton; Ron Akehurst; Mark Sculpher; John Brazier
Journal:  J Health Serv Res Policy       Date:  2007-01
View more
  3 in total

1.  Should the Lambda (λ) Remain Silent?

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

2.  Can the real opportunity cost stand up: displaced services, the straw man outside the room.

Authors:  Simon Eckermann; Brita Pekarsky
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

3.  Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice?

Authors:  Mike Paulden; Christopher McCabe; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.